Nasal spray similar to ketamine to be added to PBS for treatment-resistant depression

A new medication inspired by ketamine could revolutionize treatment for Australians with stubborn depression. Spravato, chemically esketamine, targets glutamate to alleviate symptoms quickly—without sedation or erasing feelings. It’s now affordable through Australia's Pharmaceutical Benefits Scheme, marking Australia's first major new antidepressant in 30 years. Expected to benefit up to 30,000 patients, this breakthrough could restore hope for those resistant to conventional treatments.